Bipolar Disorders in Primary Care Practice
Bipolar disorders are chronic mood disorders characterized by episodes of mania/hypomania and depression. For the Family Nurse Practitioner (FNP), accurate diagnosis and management are critical because these conditions often first present in primary care settings. Delayed or incorrect treatment can lead to significant morbidity, suicide risk, and psychosocial impairment.[1] High-yield exam concepts include distinguishing bipolar I from bipolar II, recognizing mixed features, selecting first-line pharmacotherapy, and monitoring for adverse effects of mood stabilizers.
Essential Mood Episode Types and Features
- Mania: A distinct period of abnormally elevated, expansive, or irritable mood lasting at least 1 week (or less if hospitalization is required). Associated with increased goal-directed activity, grandiosity, decreased need for sleep, and impaired judgment.[2]
- Hypomania: A milder form of mania lasting at least 4 consecutive days that does not cause marked social or occupational impairment or require hospitalization.[2]
- Mixed Features: The presence of both manic/hypomanic and depressive symptoms during the same episode, or rapidly alternating within 24 hours.[2]
- Rapid Cycling: Four or more mood episodes within a 12-month period. More common in women and associated with poorer treatment response.[3]
DSM-5-TR Classification of Bipolar Subtypes
Bipolar I Disorder
- At least one manic episode (may have prior or subsequent hypomanic or depressive episodes).[2]
- Mania causes significant distress or functional impairment, often requiring hospitalization or involving psychotic features.
Bipolar II Disorder
- At least one hypomanic episode and one major depressive episode.[2]
- No history of a full manic episode.
- Depressive episodes typically cause more impairment than hypomanic episodes.
Cyclothymic Disorder
- Chronic, fluctuating mood disturbance with numerous periods of hypomanic and depressive symptoms that do not meet full criteria for a hypomanic or major depressive episode, lasting ≥2 years (≥1 year in children/adolescents).[2]
Manic and Depressive Episode Symptom Profiles
Manic Episode
- Elevated or irritable mood
- Grandiosity or inflated self-esteem
- Decreased need for sleep (e.g., feels rested after 3 hours)
- Pressured speech, racing thoughts, flight of ideas
- Increase in goal-directed activity (social, work, sexual)
- Excessive involvement in pleasurable activities with high potential for painful consequences (e.g., spending sprees, risky investments, sexual indiscretions)
- Poor insight and judgment
Depressive Episode
- Depressed mood most of the day, nearly every day
- Anhedonia (loss of interest or pleasure)
- Significant weight loss/gain or appetite change
- Insomnia or hypersomnia
- Fatigue or loss of energy
- Feelings of worthlessness or excessive guilt
- Diminished concentration or indecisiveness
- Recurrent thoughts of death or suicide
Primary Care Screening Tools and Medical Rule-Out
- Mood Disorder Questionnaire (MDQ): A 13-item validated screening tool for bipolar spectrum disorders. A positive screen should prompt a full diagnostic interview.[4]
- Patient Health Questionnaire-9 (PHQ-9) can detect depressive symptoms but is not diagnostic for bipolar disorder; use caution to avoid treating bipolar depression with antidepressant monotherapy.
- Rule out medical causes: Perform a thorough history, review of systems, and basic labs (CBC, CMP, TSH, vitamin B12, folate, urine toxicology) to exclude secondary mania or depression (e.g., hyperthyroidism, substance use, medication-induced).[5]
Acute and Long-Term Medication Management
| Phase | First-Line Medications | Key Points |
|---|---|---|
| Mania (Acute) | Lithium, Valproate, Atypical antipsychotics (e.g., olanzapine, quetiapine, risperidone) | Lithium requires monitoring of renal function, thyroid, and serum levels. Valproate requires liver function and CBC monitoring.[6] |
| Bipolar Depression | Quetiapine, Olanzapine/fluoxetine combination (Symbyax), Lurasidone | Avoid antidepressant monotherapy due to risk of switching to mania or rapid cycling. Lithium also effective for acute depression maintenance.[7] |
| Maintenance/Prophylaxis | Lithium, Valproate, Lamotrigine, Atypical antipsychotics | Lamotrigine is not effective for acute mania but excellent for depression prophylaxis. Slow titration required to reduce Stevens-Johnson syndrome risk.[6] |
Psychotherapy
- Psychoeducation (for patient and family) improves medication adherence and relapse prevention.[8]
- Cognitive-behavioral therapy (CBT) and Interpersonal and social rhythm therapy (IPSRT) are effective adjunctive treatments.
Risk Monitoring and Adverse Effect Prevention
- Suicide risk: Highest in mixed states or during depressive episodes. Assess for suicidal ideation, plan, means, and intent at every visit.[3]
- Antidepressant-induced mania: Avoid SSRI/SNRI monotherapy in bipolar depression unless combined with a mood stabilizer or antipsychotic.
- Lithium toxicity: Monitor serum levels (therapeutic 0.6–1.2 mEq/L). Toxicity signs: nausea, tremor, ataxia, confusion, renal failure. Evaluate kidney and thyroid function regularly.
- Valproate: Hepatotoxicity, pancreatitis, teratogenicity (avoid in pregnancy). Monitor liver enzymes, CBC, and pregnancy status in women of childbearing age.
- Lamotrigine: Titrate slowly (starting 25 mg/day) to minimize risk of Stevens-Johnson syndrome. Discontinue immediately if rash appears.
Test-Taking Strategies and Diagnostic Distinctions
- Differentiate bipolar I vs II: Remember that bipolar II requires a hypomanic episode (<4 days) and no mania; bipolar I requires at least one manic episode.
- First-line for bipolar depression: Quetiapine and lurasidone are preferred over antidepressants. The combination olanzapine/fluoxetine is an option but watch for metabolic side effects.
- Lithium facts: It is the gold standard for maintenance and reduces suicide risk. Monitor thyroid (TSH) and renal function (Cr, eGFR) every 3–6 months.
- Rapid cycling: More common in females; often requires valproate or combination therapy. Antidepressants may worsen cycling.
- Mixed features: Treat with mood stabilizers and atypical antipsychotics; antidepressants are generally avoided.
- Memory aid for mania: DIG FAST — Distractibility, Grandiosity, Flight of ideas, Activity increased, Sleep deficit, Talkativeness (pressured speech).
References and Sources
- American Psychiatric Association. (2022). Diagnostic and Statistical Manual of Mental Disorders (5th ed., text rev.). https://doi.org/10.1176/appi.books.9780890425787
- American Psychiatric Association. (2022). Bipolar and Related Disorders. In DSM-5-TR. https://www.psychiatry.org/patients-families/bipolar-disorders
- Grande, I., Berk, M., Birmaher, B., & Vieta, E. (2016). Bipolar disorder. The Lancet, 387(10027), 1561–1572. https://doi.org/10.1016/S0140-6736(15)00241-X
- Hirschfeld, R. M. A., Williams, J. B. W., Spitzer, R. L., et al. (2000). Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. American Journal of Psychiatry, 157(11), 1873–1875. https://doi.org/10.1176/appi.ajp.157.11.1873
- Goodwin, F. K., & Jamison, K. R. (2007). Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression (2nd ed.). Oxford University Press.
- Yatham, L. N., Kennedy, S. H., Parikh, S. V., et al. (2018). Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disorders, 20(2), 97–170. https://doi.org/10.1111/bdi.12609
- Geddes, J. R., & Miklowitz, D. J. (2013). Treatment of bipolar disorder. The Lancet, 381(9878), 1672–1682. https://doi.org/10.1016/S0140-6736(13)60857-0
- Miklowitz, D. J., & Scott, J. (2009). Psychosocial treatments for bipolar disorder: cost-effectiveness, mediating mechanisms, and future directions. Bipolar Disorders, 11(Suppl 2), 110–122. https://doi.org/10.1111/j.1399-5618.2009.00715.x